Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Significant Decline in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 42,300 shares, a decrease of 23.8% from the February 13th total of 55,500 shares. Based on an average trading volume of 63,400 shares, the days-to-cover ratio is currently 0.7 days. Currently, 2.3% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lixte Biotechnology stock. Atlas Legacy Advisors LLC purchased a new stake in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned 0.56% of Lixte Biotechnology as of its most recent filing with the Securities and Exchange Commission (SEC). 5.10% of the stock is owned by institutional investors.

Lixte Biotechnology Stock Up 3.8 %

LIXT stock traded up $0.05 during midday trading on Tuesday, reaching $1.27. The company had a trading volume of 10,851 shares, compared to its average volume of 317,688. The stock has a 50 day moving average price of $1.88 and a 200 day moving average price of $1.90. The firm has a market capitalization of $2.85 million, a PE ratio of -0.73 and a beta of 0.19. Lixte Biotechnology has a fifty-two week low of $1.02 and a fifty-two week high of $4.40.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.